Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study

Date

21 Oct 2023

Session

Poster session 11

Topics

Tumour Site

Neuroendocrine Neoplasms

Presenters

Valentina Andreasi

Citation

Annals of Oncology (2023) 34 (suppl_2): S498-S502. 10.1016/S0923-7534(23)01261-9

Authors

V. Andreasi1, S. Partelli1, M. Schiavo Lena2, F. Muffatti1, A. Battistella1, D. Tamburrino1, N. Pecorelli1, S. Crippa1, G. Balzano1, C. Doglioni2, M. Falconi1

Author affiliations

  • 1 Pancreatic Surgery Unit, IRCCS San Raffaele Scientific Institute, 20132 - Milan/IT
  • 2 Pathology Unit, IRCCS San Raffaele Scientific Institute, 20132 - Milan/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 729P

Background

Nodal metastases (N+) are one of the most powerful predictors of disease recurrence after surgery for non-functioning pancreatic neuroendocrine tumors (NF-PanNETs). However, the prognostic role of nodal metastases < 5 mm, defined as micrometastases, has been poorly investigated so far. The aim of this study was to compare clinico-pathological features and survival outcomes between patients with NF-PanNETs without nodal involvement (N0), with nodal micrometastases (microN+) and with nodal macrometastases (macroN+).

Methods

Consecutive patients who underwent a formal pancreatic resection for NF-PanNETs at San Raffaele Hospital (Milan, Italy) between 2018 and 2021 and were enrolled in the DETECTYON trial were considered (NCT03918759). Nodal metastases were further classified as microN+ when their maximum diameter was < 5 mm, or as macroN+ when their maximum diameter was ≥ 5 mm.

Results

Overall, 100 patients were included. Of these, 58 had N0 PanNETs, 15 had microN+ and 27 had macroN+. Patients with macroN+ had significantly larger tumors [median 35 mm (IQR 28-47)] as compared to patients with microN+ [25 mm (IQR 24-35), p=0.040] and N0 neoplasms (26 mm (IQR 18-34), p=0.003]. The rate of G2-G3 neoplasms was comparable between patients with N0 and microN+ PanNETs (45% versus 27%, p=0.203), whereas it was significantly higher among subjects with macroN+ tumors (n=21/27 - 78%). Median Ki67 was 2% in patients with N0 and microN+ neoplasms (p=0.429), whereas it increased to 6% in patients with macroN+ (p=0.006). After a median follow-up of 37 months, 16 patients (16%) experienced disease relapse. Patients with N0 PanNETs had a 4-year DFS rate of 97% as compared with 88% and 43% in patients with microN+ (p=0.152) and macroN+ (p<0.001), respectively. At multivariable analysis, distant metastases (HR 5.826, p=0.026) and macroN+ (HR 6.281, p=0.034) were identified as independent determinants of disease relapse.

Conclusions

NF-PanNETs with microN+ seem to be associated with a risk of recurrence similar to N0 neoplasms. MicroN+ may be regarded as a clinicopathological entity separate from macroN+, with a possible impact on postoperative surveillance protocols.

Clinical trial identification

These are the long-term outcomes of a prospective observational study: NCT03918759.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.